Jenny Pan-Yun Ting

Jenny Pan-Yun Ting

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Jenny Pan-Yun Ting

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2019 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
KSKaren V. Swanson
Karen V. Swanson
MDMeng Deng
Meng Deng
JTJenny P.-Y. Ting
Jenny P.-Y. Ting

29 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HGHaitao Guo
Haitao Guo
JCJustin B Callaway
Justin B Callaway
JTJenny P-Y Ting
Jenny P-Y Ting

10 April 2011 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
HWHaitao Wen
Haitao Wen
DGDenis Gris
Denis Gris
YLYu L. Lei
Yu L. Lei
SJSushmita Jha
Sushmita Jha
LZLu Zhang
Lu Zhang
JTJenny P-Y Ting
Jenny P-Y Ting

23 April 2011 in Annual Review of Immunology
Verified
Journal Article
Closed access
BDBeckley K. Davis
Beckley K. Davis
HWHaitao Wen
Haitao Wen
JTJenny P.-Y. Ting
Jenny P.-Y. Ting
Inflammasome activation leads to caspase-1 activation, which causes the maturation and secretion of pro-IL-1β and pro-IL-18 among other substrates. A subgroup of the NLR (nucleotide-binding domain, leucine-rich repeat containing) proteins are key mediators of the inflammasome. Studies of gene-deficient mice and cells have implicated NLR inflammasomes in a host of responses to a wide range of microbial pathogens, inflammatory diseases, cancer, and metabolic and autoimmune disorders. Determining exactly how the inflammasome is activated in these diseases and disease models remains a challenge. This review presents and integrates recent progress in the field.

1 March 2008 in Immunity
Verified
Journal Article
Closed access
JTJenny P.-Y. Ting
Jenny P.-Y. Ting
RLRuth Caroline Lovering
Ruth Caroline Lovering
EAEmad S. Alnemri
Emad S. Alnemri
JBJohn Bertin
John Bertin
JBJeremy M. Boss
Jeremy M. Boss
Peter A WardPeter A Ward
Peter A Ward

10 October 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CCCasey M. Clements
Casey M. Clements
RMRichard S. McNally
Richard S. McNally
BCBrian J. Conti
Brian J. Conti
TMTak W. Mak
Tak W. Mak
JTJenny P.-Y. Ting
Jenny P.-Y. Ting
DJ-1/PARK7, a cancer- and Parkinson's disease (PD)-associated protein, protects cells from toxic stresses. However, the functional basis of this protection has remained elusive. We found that loss of DJ-1 leads to deficits in NQO1 [NAD(P)H quinone oxidoreductase 1], a detoxification enzyme. This deficit is attributed to a loss of Nrf2 (nuclear factor erythroid 2-related factor), a master regulator of antioxidant transcriptional responses. DJ-1 stabilizes Nrf2 by preventing association with its inhibitor protein, Keap1, and Nrf2's subsequent ubiquitination. Without intact DJ-1, Nrf2 protein is unstable, and transcriptional responses are thereby decreased both basally and after induction. This effect of DJ-1 on Nrf2 is present in both transformed lines and primary cells across human and mouse species. DJ-1's effect on Nrf2 and subsequent effects on antioxidant responses may explain how DJ-1 affects the etiology of both cancer and PD, which are seemingly disparate disorders. Furthermore, this DJ-1/Nrf2 functional axis presents a therapeutic target in cancer treatment and justifies DJ-1 as a tumor biomarker.